Vext Science Inc

Vext Science Inc has a debt-to-equity ratio of 0.44, indicating a relatively conservative capital structure with a moderate reliance on debt financing. The company's current ratio of 1.76 suggests it has sufficient short-term assets to cover its short-term liabilities, though its operating cash flow of $109,040 and free cash flow of -$2.82 million indicate limited liquidity and cash generation capacity. The negative free cash flow is a concern, as it suggests the company is spending more on operations and capital expenditures than it is generating in cash.

The company's profitability metrics are weak, with a return on equity (ROE) of -7.14% and a return on assets (ROA) of -4.36%. These figures are below the typical thresholds for healthy performance in the pharmaceutical industry, which often emphasizes high ROE and ROA due to the capital-intensive nature of drug development and production. The operating loss of $5.26 million and net loss of $6.33 million further underscore the company's current financial challenges.

Vext Science Inc's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no material geographic diversification reported. This lack of diversification increases the company's exposure to market-specific risks, particularly in the pharmaceutical sector, where regulatory and competitive pressures can significantly impact revenue streams.

The company's growth trajectory is uncertain, with no significant revenue growth reported in the latest financial period. The operating cash flow and free cash flow figures suggest that the company is not generating enough cash to sustain operations without external financing. The outlook for the next fiscal year remains cautious, with no clear indicators of a turnaround in profitability or cash flow generation.

The risk assessment for Vext Science Inc highlights medium liquidity risk and low dilution risk. The company's net cash position is negative after accounting for total debt, which could limit its ability to fund operations or pursue growth opportunities without additional financing. The low dilution risk is attributed to the absence of significant dilutive events in the recent financial statements, although the company's reliance on external financing could change this outlook.

Recent events, including the latest financial filings, indicate that the company is operating in a challenging environment. The lack of strong buy recommendations from analysts and the uniform price target of $0.40 suggest limited investor confidence in the company's near-term prospects. The absence of buy or hold recommendations further reinforces the cautious stance of the market.

Revenue surged 42.7% year-over-year to $51.4 million, demonstrating strong top-line growth momentum in the latest fiscal period.

Analysts project 45.5% upside to a $0.40 target price, reflecting positive market sentiment and buy recommendations.

Long-term debt decreased to $35.0 million in FY2026, indicating a reduction in leverage compared to the prior year.

The debt-to-equity ratio of 0.44 remains below the healthcare cohort median of 0.32, suggesting manageable leverage levels.

Dilution risk is assessed as low, providing some protection for existing shareholders against equity value erosion.

Operating income turned negative at -$12.0 million in FY2024, highlighting a significant deterioration in core operational performance.

Credit risk is flagged as high, indicating substantial concerns regarding the company's ability to meet its financial obligations.

Free cash flow swung negative to -$5.7 million in FY2026, reversing the positive cash generation seen in previous years.

Revenue $13.7M, +34,7% YoY; Operating income −417,9% YoY.

• ▍Revenue $13.7M, +34,7% YoY
• ▍Operating income −417,9% YoY
• ▍Net income −14,6% YoY
• ▍Free cash flow +5,5% YoY
• ▍Net margin -76.9%

Revenue $12.7M, +41,0% YoY; Operating income −13,6% YoY.

• ▍Revenue $12.7M, +41,0% YoY
• ▍Operating income −13,6% YoY
• ▍Net income −5,3% YoY
• ▍Free cash flow −77,9% YoY
• ▍Net margin -20.7%

Revenue $13.4M, +59,1% YoY; Operating income +87,3% YoY.

• ▍Revenue $13.4M, +59,1% YoY
• ▍Operating income +87,3% YoY
• ▍Net income +66,3% YoY
• ▍Free cash flow +309,1% YoY
• ▍Net margin -11.0%

Revenue $11.6M, +37,8% YoY; Operating income +59,3% YoY.

• ▍Revenue $11.6M, +37,8% YoY
• ▍Operating income +59,3% YoY
• ▍Net income +47,4% YoY
• ▍Free cash flow +85,6% YoY
• ▍Net margin -28.8%

Revenue $10.2M; Operating income -$1.5M.

• ▍Revenue $10.2M
• ▍Operating income -$1.5M
• ▍Net margin -90.4%

Revenue $9.0M; Operating income -$1.3M.

• ▍Revenue $9.0M
• ▍Operating income -$1.3M
• ▍Net margin -27.8%

Revenue $8.4M; Operating income -$3.8M.

• ▍Revenue $8.4M
• ▍Operating income -$3.8M
• ▍Net margin -52.1%

Revenue $8.4M; Operating income -$5.3M.

• ▍Revenue $8.4M
• ▍Operating income -$5.3M
• ▍Net margin -75.5%

Revenue $51.4M, +42,7% YoY; Operating income −1,1% YoY.

• ▍Revenue $51.4M, +42,7% YoY
• ▍Operating income −1,1% YoY
• ▍Net income +19,8% YoY
• ▍Free cash flow +34,8% YoY
• ▍Net margin -35.0%

Revenue $36.0M, +3,4% YoY; Operating income +6,5% YoY.

• ▍Revenue $36.0M, +3,4% YoY
• ▍Operating income +6,5% YoY
• ▍Net income −610,1% YoY
• ▍Free cash flow −177,5% YoY
• ▍Net margin -62.3%

Revenue $34.8M, −1,7% YoY; Operating income −239,2% YoY.

• ▍Revenue $34.8M, −1,7% YoY
• ▍Operating income −239,2% YoY
• ▍Net income −59,7% YoY
• ▍Free cash flow +29,7% YoY
• ▍Net margin 12.6%

Revenue $35.4M, −4,9% YoY; Operating income +30,2% YoY.

• ▍Revenue $35.4M, −4,9% YoY
• ▍Operating income +30,2% YoY
• ▍Net income +119,0% YoY
• ▍Free cash flow +182,6% YoY
• ▍Net margin 30.8%